Lawyers acting on behalf of Veeva have filed a motion to extend the reach of the suit to include additional Veeva software applications that they allege Iqvia bars clients from using with Iqvia-derived data.
The legal action accuses Iqvia of preventing use of using OneKey reference data with Veeva Network Customer Master data management software. Also, the suit alleges, Iqvia two years ago started restricting use of any Iqvia data with Veeva’s Nitro commercial data warehouse, Andi artificial intelligence (AI) application, and other applications.
Paul Shawah, senior vice president of commercial strategy with Veeva, told Outsourcing-Pharma the “abusive” conduct that the suit alleges Iqvia engaged in impedes the progress of clinical trials and, ultimately, harms patients.
“Pharma manufacturers are experts in the diseases they treat. They may use diverse data sets such as patient claims, prescription history, lab data, and EHR data, for example, to identify patterns that indicate that a patient is at higher risk of a specific disease,” he said
Shawah added that by allegedly preventing pharma manufacturers and other parties from incorporating Iqvia data in Veeva software, professionals cannot attain the information needed to identify and treat patients.
“Ultimately, this is bad for patients and slows or prevents them from getting the treatments they need,” he said.
In a discussion with Outsourcing-Pharma, Harvey Ashman, senior vice president and deputy general counsel of Iqvia, fired back at the charges leveled by Veeva Systems.
“This filing is just another example of Veeva's established pattern of deceptive and dishonest behavior, ranging from stealing trade secrets to destroying evidence to trying to smear our name with meritless accusations,” he told us.
According to a Veeva representative, the trial is anticipated to take place in late 2021.